Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies
- 9 December 2008
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 80 (4), 412-416
- https://doi.org/10.1136/jnnp.2007.138016
Abstract
Objective: Anti-Hu antibodies (Hu-Ab) and anti-CV2/CRMP5 antibodies (CV2/CRMP5-Ab) have been identified in association with paraneoplastic neurological disorders. However, it is not clear whether these antibodies are associated with specific neurological symptoms or are only markers of anti-cancer immune reaction. Methods: To address this question, 37 patients with CV2/CRMP5-Ab and 324 patients with Hu-Ab were compared. Results: Whereas the age and sex ratio were the same between the two groups, the distribution of neurological symptoms was not. Patients with CV2/CRMP5-Ab presented more frequently cerebellar ataxia, chorea, uveo/retinal symptoms and myasthenic syndrome (Lambert–Eaton myasthenic syndrome LEMS or myasthenia gravis). They also had a better Rankin score. In contrast, dysautonomia, brainstem encephalitis and peripheral neuropathy were more frequent in patients with Hu-Ab. Limbic encephalitis occurred similarly in both groups. Small-cell lung cancer was the most frequently associated tumour in both groups of patients, while malignant thymoma was observed only in patients with CV2/CRMP5-Ab. In particular, patients with CV2/CRMP5-Ab and thymoma developed myasthenic syndrome more frequently, while patients with SCLC developed neuropathies more frequently. Chorea and myasthenic syndrome were only seen in patients with CV2/CRMP5-Ab. The median survival time was significantly longer in patients with CV2/CRMP5-Ab, and this effect was not dependent on the type of tumour. Interpretation: The data demonstrate that in patients with paraneoplastic neurological syndromes, the neurological symptoms and survival vary with both the type of associated onco-neural antibody and the type of tumour.Keywords
This publication has 20 references indexed in Scilit:
- Expression of the onconeural CV2/CRMP5 antigen in thymus and thymomaJournal of Neuroimmunology, 2006
- Paraneoplastic antibodies coexist and predict cancer, not neurological syndromeAnnals of Neurology, 2004
- Recommended diagnostic criteria for paraneoplastic neurological syndromesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Paraneoplastic movement disorder in a patient with non‐Hodgkin's lymphoma and CRMP‐5 autoantibodyMovement Disorders, 2003
- Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP‐5‐IgGAnnals of Neurology, 2003
- Paraneoplastic chorea associated with CRMP‐5 neuronal antibody and lung carcinomaAnnals of Neurology, 2002
- Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodiesBrain, 2002
- Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retinaJournal of the Neurological Sciences, 1993
- PRIMARY SENSORY NEUROPATHY WITH MUSCULAR CHANGES ASSOCIATED WITH CARCINOMAJournal of Neurology, Neurosurgery & Psychiatry, 1948